vs
SIMMONS FIRST NATIONAL CORP（SFNC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
SIMMONS FIRST NATIONAL CORP的季度营收约是再鼎医药的1.6倍（$197.3M vs $127.1M），SIMMONS FIRST NATIONAL CORP同比增速更快（19.6% vs 17.1%），SIMMONS FIRST NATIONAL CORP自由现金流更多（$411.4M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 0.6%）
西蒙斯第一国民公司是一家银行控股企业，旗下核心子公司西蒙斯银行的业务覆盖阿肯色州、堪萨斯州、密苏里州、俄克拉荷马州、田纳西州及得克萨斯州，为当地客户提供各类银行相关金融服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
SFNC vs ZLAB — 直观对比
营收规模更大
SFNC
是对方的1.6倍
$127.1M
营收增速更快
SFNC
高出2.5%
17.1%
自由现金流更多
SFNC
多$438.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $197.3M | $127.1M |
| 净利润 | — | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | — | — |
| 营收同比 | 19.6% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.36 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SFNCZLAB
| Q4 25 | $197.3M | $127.1M | ||
| Q3 25 | $186.7M | $115.4M | ||
| Q2 25 | $214.2M | $109.1M | ||
| Q1 25 | $209.6M | $105.7M | ||
| Q4 24 | $208.5M | $108.5M | ||
| Q3 24 | $174.8M | $101.8M | ||
| Q2 24 | $197.2M | $100.1M | ||
| Q1 24 | $195.1M | $87.1M |
净利润SFNCZLAB
| Q4 25 | — | — | ||
| Q3 25 | $-562.8M | $-36.0M | ||
| Q2 25 | $54.8M | $-40.7M | ||
| Q1 25 | $32.4M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $24.7M | $-41.7M | ||
| Q2 24 | $40.8M | $-80.3M | ||
| Q1 24 | $38.9M | $-53.5M |
毛利率SFNCZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率SFNCZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | — | -42.3% | ||
| Q2 25 | — | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | — | -66.6% | ||
| Q2 24 | — | -76.0% | ||
| Q1 24 | — | -80.7% |
净利率SFNCZLAB
| Q4 25 | — | — | ||
| Q3 25 | -301.5% | -31.2% | ||
| Q2 25 | 25.6% | -37.3% | ||
| Q1 25 | 15.5% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 14.1% | -40.9% | ||
| Q2 24 | 20.7% | -80.2% | ||
| Q1 24 | 19.9% | -61.4% |
每股收益（稀释后）SFNCZLAB
| Q4 25 | $0.36 | $-0.05 | ||
| Q3 25 | $-4.00 | $-0.03 | ||
| Q2 25 | $0.43 | $-0.04 | ||
| Q1 25 | $0.26 | $-0.04 | ||
| Q4 24 | $0.38 | $-0.09 | ||
| Q3 24 | $0.20 | $-0.04 | ||
| Q2 24 | $0.32 | $-0.08 | ||
| Q1 24 | $0.31 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $620.0M | — |
| 股东权益账面价值 | $3.4B | $715.5M |
| 总资产 | $24.5B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.18× | — |
8季度趋势，按日历期对齐
现金及短期投资SFNCZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务SFNCZLAB
| Q4 25 | $620.0M | — | ||
| Q3 25 | $667.8M | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.2B | — |
股东权益SFNCZLAB
| Q4 25 | $3.4B | $715.5M | ||
| Q3 25 | $3.4B | $759.9M | ||
| Q2 25 | $3.5B | $791.7M | ||
| Q1 25 | $3.5B | $810.8M | ||
| Q4 24 | $3.5B | $840.9M | ||
| Q3 24 | $3.5B | $667.7M | ||
| Q2 24 | $3.5B | $704.2M | ||
| Q1 24 | $3.4B | $762.2M |
总资产SFNCZLAB
| Q4 25 | $24.5B | $1.2B | ||
| Q3 25 | $24.2B | $1.2B | ||
| Q2 25 | $26.7B | $1.2B | ||
| Q1 25 | $26.8B | $1.2B | ||
| Q4 24 | $26.9B | $1.2B | ||
| Q3 24 | $27.3B | $985.3M | ||
| Q2 24 | $27.4B | $987.4M | ||
| Q1 24 | $27.4B | $988.4M |
负债/权益比SFNCZLAB
| Q4 25 | 0.18× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.28× | — | ||
| Q1 25 | 0.35× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.40× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $449.5M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $411.4M | $-26.7M |
| 自由现金流率自由现金流/营收 | 208.5% | -21.0% |
| 资本支出强度资本支出/营收 | 19.3% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $717.0M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流SFNCZLAB
| Q4 25 | $449.5M | $-26.0M | ||
| Q3 25 | $223.4M | $-32.0M | ||
| Q2 25 | $77.6M | $-31.0M | ||
| Q1 25 | $32.8M | $-61.7M | ||
| Q4 24 | $425.9M | $-55.8M | ||
| Q3 24 | $199.4M | $-26.8M | ||
| Q2 24 | $86.1M | $-42.2M | ||
| Q1 24 | $57.6M | $-90.1M |
自由现金流SFNCZLAB
| Q4 25 | $411.4M | $-26.7M | ||
| Q3 25 | $216.7M | $-35.0M | ||
| Q2 25 | $66.3M | $-33.9M | ||
| Q1 25 | $22.6M | $-63.2M | ||
| Q4 24 | $380.4M | $-58.4M | ||
| Q3 24 | $187.7M | $-28.2M | ||
| Q2 24 | $72.7M | $-42.9M | ||
| Q1 24 | $47.7M | $-91.1M |
自由现金流率SFNCZLAB
| Q4 25 | 208.5% | -21.0% | ||
| Q3 25 | 116.1% | -30.4% | ||
| Q2 25 | 31.0% | -31.1% | ||
| Q1 25 | 10.8% | -59.9% | ||
| Q4 24 | 182.5% | -53.8% | ||
| Q3 24 | 107.4% | -27.7% | ||
| Q2 24 | 36.9% | -42.9% | ||
| Q1 24 | 24.5% | -104.5% |
资本支出强度SFNCZLAB
| Q4 25 | 19.3% | 0.5% | ||
| Q3 25 | 3.6% | 2.6% | ||
| Q2 25 | 5.3% | 2.6% | ||
| Q1 25 | 4.8% | 1.5% | ||
| Q4 24 | 21.8% | 2.4% | ||
| Q3 24 | 6.7% | 1.3% | ||
| Q2 24 | 6.8% | 0.7% | ||
| Q1 24 | 5.0% | 1.1% |
现金转化率SFNCZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.42× | — | ||
| Q1 25 | 1.01× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.06× | — | ||
| Q2 24 | 2.11× | — | ||
| Q1 24 | 1.48× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SFNC
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
